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Trends and clinical characteristics of 57.9 million 
COVID-19 vaccine recipients:
a federated analysis of patients’ primary care records in situ using OpenSAFELY
INTRODUCTION
On 8 December 2020, the NHS in England 
administered the first COVID-19 vaccination 
as part of an ambitious vaccine programme 
to combat the ongoing pandemic owing 
to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Vaccination 
is one of the most cost-effective ways of 
avoiding disease, and worldwide vaccinations 
prevent 2–3 million deaths per year, but new 
vaccines can take many years or decades to 
develop and become part of routine practice.1 
Since the outset of the COVID-19 pandemic, 
teams of scientists, clinical trialists, and 
regulators around the world have worked 
at unprecedented speed, with >200 
vaccines currently being tested.2 The UK 
medicines regulator approved two COVID- 19 
vaccines for use before the end of 2020: 
the Pfizer-BioNTech mRNA vaccine and the 
AstraZeneca-Oxford vaccine.3 The Moderna 
vaccine was subsequently approved in 
January 2021,4 with more vaccine approvals 
during 2021.
For the UK the independent Joint 
Committee on Vaccination and Immunisation 
(JCVI) provides recommendations on 
vaccinations to the government and 
England’s NHS. In early December 2020 the 
JCVI recommended nine priority groups for 
vaccination (Box 1), largely based on risk of 
death from COVID-19.5 This was the basis for 
the NHS England vaccination programme, 
with due recognition that vaccination of care 
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Background
On 8 December 2020 NHS England administered 
the first COVID-19 vaccination.
Aim
To describe trends and variation in vaccine 
coverage in different clinical and demographic 
groups in the first 100 days of the vaccine rollout.
Design and setting
With the approval of NHS England, a cohort 
study was conducted of 57.9 million patient 
records in general practice in England, in situ and 
within the infrastructure of the electronic health 
record software vendors EMIS and TPP using 
OpenSAFELY.
Method
Vaccine coverage across various subgroups 
of Joint Committee on Vaccination and 
Immunisation (JCVI) priority cohorts is described.
Results
A total of 20 852 692 patients (36.0%) received 
a vaccine between 8 December 2020 and 17 
March 2021. Of patients aged ≥80 years not in 
a care home (JCVI group 2) 94.7% received a 
vaccine, but with substantial variation by ethnicity 
(White 96.2%, Black 68.3%) and deprivation (least 
deprived 96.6%, most deprived 90.7%). Patients 
with pre-existing medical conditions were more 
likely to be vaccinated with two exceptions: severe 
mental illness (89.5%) and learning disability 
(91.4%). There were 275 205 vaccine recipients 
who were identified as care home residents (JCVI 
group 1; 91.2% coverage). By 17 March, 1 257 914 
(6.0%) recipients had a second dose. 
Conclusion
The NHS rapidly delivered mass vaccination. In 
this study a data-monitoring framework was 
deployed using publicly auditable methods and 
a secure in situ processing model, using linked 
but pseudonymised patient-level NHS data for 
57.9 million patients. Targeted activity may be 
needed to address lower vaccination coverage 
observed among certain key groups. 
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home residents may initially lag behind other 
groups because of complexities around 
storing and distributing Pfizer-BioNTech 
outside of larger healthcare settings 
without appropriate cold chain facilities.6 
Vaccinations were administered initially in 
hospitals and a number of primary care 
centres; then in GP surgeries, community 
pharmacies, and newly established mass 
vaccination centres. 
Both vaccines administered to date require 
two doses. Given high infection rates and 
the relatively high protection thought to be 
offered by the first dose, after the start of the 
campaign the JCVI recommended extending 
the interval to 12 weeks. This strategy was 
intended to prevent the most deaths and 
admissions to hospital through maximising 
the number of patients with some protection 
against the virus as quickly as possible, 
although GPs were initially allowed some 
discretion in the exact timing of the second 
dose.7,8 
OpenSAFELY is a new secure analytics 
platform for electronic patient records built 
by the authors’ group on behalf of NHS 
England to deliver urgent academic and 
operational research during the pandemic.9,10 
Analyses run across all patients’ full-coded 
pseudonymised primary care records, and 
includes 57.9 million patients, 95% of people 
registered with an English general practice, 
those where EMIS or TPP electronic health 
record (EHR) software is deployed, with 
patient-level linkage to various sources, such 
as secondary care data. Code and analysis 
are shared openly for inspection and re-use. 
Vaccine administration details are recorded 
in the National Immunisation Management 
Service (NIMS) and electronically transmitted 
to every individual’s GP record on a daily 
basis. 
OpenSAFELY can provide detailed 
information about the demographics and 
clinical conditions of those vaccinated from 
each patient’s full pseudonymised EHR, 
which is not available within NIMS. This 
can reveal whether the vaccine rollout is 
leaving certain groups behind and whether 
any targeted action is required to address 
gaps in coverage. 
This study therefore set out to: assess 
the coverage of COVID-19 vaccination in 
all patients registered with TPP and EMIS 
practices in England in near real time in 
the first 100 days of the campaign; and to 
describe how coverage varied between key 
clinical and demographic subgroups.
METHOD
Study design 
A retrospective cohort study was conducted 
using general practice primary care EHR 
data from all England GP practices supplied 
by the EHR vendors EMIS and TPP. The 
cohort study began on 8 December 2020, the 
start of the national vaccination campaign, 
and ended on 17 March 2021. The authors 
of the current study are producing weekly 
vaccine coverage reports with a subset of this 
data11 and will update this analysis regularly 
with extended follow-up time using near 
real-time data as the vaccination campaign 
progresses. 
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How this fits in 
The COVID-19 vaccination programme 
was launched in England on 8 December 
2020. Limited information is available 
on vaccination coverage in detailed 
demographic and clinical subgroups. 
This study deployed a data-monitoring 
framework for vaccine coverage using 
publicly auditable methods and secure 
in situ processing, for linked but 
pseudonymised patient-level NHS data 
on 95% of patients registered with a GP 
in England. This study highlights lower 
vaccination coverage in the first 100 days 
of the vaccine rollout among certain key 
groups: ethnic minorities, those living in 
areas of higher deprivation, and individuals 
living with severe mental illness or learning 
disabilities where targeted activity may 
be needed to ensure equitable protection 
against COVID-19.
Box 1. Priority groups for vaccination advised by the Joint 
Committee on Vaccination and Immunisation5 
Priority group Risk group
1 Residents in a care home for older adults
 Staff working in care homes for older adults
2 All those aged ≥80 years
 Frontline health and social care workers
3 All those aged ≥75 years
4a All those aged ≥70 years
  Clinically extremely vulnerable individuals (not including pregnant women and those 
aged <16 years)
5 All those aged ≥65 years
6b Adults aged 16–65 years in an at-risk group
7 All those ≥60 years
8 All those ≥55 years
9 All those ≥50 years
aIndividuals classed as clinically extremely vulnerable (priority group 4) were those advised to ‘shield’ and minimise 
risk of exposure to infection. They were given a shielding code through national algorithms, their GP, or other 
healthcare professional. bThose in at-risk groups (priority group 6) were not shielding but had other clinical 
conditions placing them at increased risk.
Data source
Primary care records managed by the GP 
software providers EMIS and TPP were 
accessed through OpenSAFELY, an open-
source data analytics platform created by 
the author team on behalf of NHS England to 
address urgent COVID-19 research questions 
(https://opensafely.org). OpenSAFELY 
provides a secure software interface allowing 
a federated analysis of pseudonymised 
primary care patient records from England 
in near real-time within the EMIS and TPP 
highly secure data environments. Non-
disclosive, aggregated results are exported 
to GitHub where further data processing 
and analysis takes place. This avoids 
the need for large volumes of potentially 
disclosive pseudonymised patient data to 
be transferred off-site. This, in addition to 
other technical and organisational controls, 
minimises any risk of re-identification.
The dataset available to the platform 
includes pseudonymised data such as coded 
diagnoses, medications, and physiological 
parameters. No free-text data are included. 
All activity on the platform is publicly logged 
and all analytic code and supporting clinical 
coding lists are automatically published. In 
addition, the framework provides assurance 
that the analysis is reproducible and reusable. 
Further details on information governance 
and platform can be found in Supplementary 
Appendix S1. 
Study population
For the descriptive analysis all patients 
registered with a general practice using EMIS 
(n = 33 873 987) or TPP (n = 24 056 480) in 
England on 17 March 2021 were included. 
Patients with unknown date of birth (that 
is default age >121 years) or unknown sex 
were excluded. 
Priority groups for vaccination
Patients were classified into their JCVI 
priority group (Box 1) using SNOMED-CT 
codelists and logic defined in the national 
COVID-19 vaccination uptake reporting 
specification developed by PRIMIS.12 Patients 
were assigned only to their highest priority 
group and not included again as part of any 
other priority group. For example, a 76-year-
old living in a care home would be assigned 
to group 1 (care home residents) but not to 
group 3 (aged 75–79 years). Eligibility was not 
assessed as defined by occupation, that is, 
health and care staff for the relevant priority 
groups (1 and 2) because this information 
is largely missing from GP records and, 
where present, is unreliable. These patients 
were therefore either classified into a lower-
priority group where applicable (for example, 
by clinical conditions or age), or as ‘other’, 
if a person did not fall into one of the nine 
defined groups. In line with the national 
reporting specification, most criteria were 
ascertained using the latest available data 
at the time of analysis, with the exception of 
age, which was calculated as at 31 March 
2021 as recommended by Public Health 
England.12
COVID-19 vaccine status
Vaccination information is transmitted back 
to patients’ primary care records in the 
days following vaccine administration in a 
designated centre. Which patients had any 
recorded COVID-19 vaccine administration 
code in their primary care record (only Pfizer-
BioNTech mRNA vaccine or AstraZeneca-
Oxford vaccine were available at the time 
of analysis) was ascertained. The latest 
available date of vaccinations recorded in 
the most recent comparable OpenSAFELY–
EMIS and OpenSAFELY–TPP database build 
were included for those vaccinated up to 
17 March 2021. Any COVID-19 vaccination 
within 19 days of the first dose was classed 
as a duplicate record entry, and the first 
vaccination after this date as the second 
dose of the schedule. 
Key demographic and clinical 
characteristics of vaccinated groups
All patient demographics defined by the 
national reporting specification (for example, 
ethnicity) were extracted. Demographics not 
defined by the specification, including the 
level of deprivation, were also extracted. 
Deprivation was measured by the Index of 
Multiple Deprivation (IMD, in quintiles, with 
higher values indicating greater deprivation), 
derived from the patient’s postcode at Lower 
Super Output Area. Patients with missing 
data were grouped into an unknown category. 
The population was also described 
according to the presence or absence of 
various pre-existing health problems: chronic 
cardiac disease; diabetes; chronic kidney 
disease; severe mental illness; learning 
disabilities; chronic neurological disease 
(including stroke); asplenia; morbid obesity; 
chronic liver disease; chronic respiratory 
disease; and immunosuppression. Patients 
lacking codes in their primary care record 
indicating these conditions were assumed to 
be free of these conditions. 
Factors associated with time to COVID-19 
vaccination
To examine relationships between multiple 
patient characteristics in older adults and 
the chance of receiving a first COVID-19 
vaccine by 17 March 2021, a federated 
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survival analysis was carried out with 
individual Cox regression models fitted 
to the TPP and EMIS datasets, before 
combining model coefficients using inverse-
variance-weighting. Here, patients were 
included who were registered in England 
and aged ≥70 years on 7 December 2020 
(n = 7 152 830, Supplementary Figure S1) 
and censored at death or deregistration. 
Patients aged <70 years were excluded 
because of the inability to ascertain health/
care worker status, a strong determinant 
of early vaccination. Patients with <1 year 
of prior follow-up were excluded to 
ensure completeness of clinical records 
(n = 237 940), and care home or nursing 
home residents (n = 154 123) were excluded 
as the vaccine rollout was organised 
separately for these individuals. All key 
demographic and clinical characteristics 
described in the section above were included 
in the multivariable model, with age grouped 
into 5-year age bands. Patients with missing 
sex or IMD (n = 59 386) were excluded. The 
model was stratified by GP practice. Hazard 
ratios from the fully adjusted model are 
reported with 95% confidence intervals (CIs). 
Codelists and implementation
Information on all characteristics were 
obtained from primary care records by 
searching TPP SystmOne and EMIS 
records for specific coded data. EMIS and 
TPP SystmOne are fully compliant with the 
mandated NHS standard of SNOMED-CT 
clinical terminology. Medicines are entered 
or prescribed in a format compliant with 
the NHS Dictionary of Medicines and 
Devices (dm+d).13 Codelists and logic for 
most features in the national reporting 




Charts of vaccine coverage were generated 
for all underlying conditions and medicines. 
Those not presented in this manuscript 
are available online for inspection in the 
associated GitHub repository.14 
Software and reproducibility
Data management and analysis was 
performed using the OpenSAFELY software 
libraries and Jupyter notebooks, implemented 
using Python 3 and R (version 4.0.2). More 
details are available in Supplementary Data 
and openly accessible GitHub repository. This 
is the first analysis delivered using federated 
analysis through the OpenSAFELY platform: 
codelists and code for data management 
and data analysis were specified once using 
the OpenSAFELY tools; then transmitted 
securely from the OpenSAFELY jobs server 
to the OpenSAFELY–TPP platform within 
TPP’s secure environment, and separately 
to the OpenSAFELY–EMIS platform within 
EMIS’s secure environment, where they 
were each executed separately against local 
patient data; summary results were then 
reviewed for disclosiveness, released, and 
combined for the final outputs. 
All code for the OpenSAFELY platform 
for data management, analysis, and secure 
code execution is shared for review and 
re-use under open licences at GitHub.com/
OpenSAFELY. All code for data management 
and analysis for this article is shared for 
scientific review and re-use under open 
licences on GitHub (https://github.com/
opensafely/covid19-vaccine-coverage-tpp-
emis). 
Patient and public involvement
Patients were not formally involved in 
developing this specific study design that 
was developed rapidly in the context of the 
rapid vaccine rollout during a global health 
emergency. The authors have developed 
a publicly available website (https://
opensafely.org) through which any patient 
or member of the public is invited to make 
contact regarding this study or the broader 
OpenSAFELY project.
RESULTS
COVID-19 vaccine coverage in JCVI priority 
groups 
A total of 20 852 692 (36.0%) patients 
registered at an EMIS or TPP practice 
received their first COVID-19 vaccine up 
to 17 March 2021 (Table 1, Figure 1). Of 
these, 275 205 were identified as living in a 
care home (group 1, 91.2% coverage of all 
care home residents), 2 422 476 were aged 
≥80 years (group 2, 94.7% of all those aged 
≥80 years not identified as living in a care 
home); and 1 865 927 were aged 75–79 years 
(group 3, 94.7% coverage). 
In later priority groups, 4 113 627 were 
identified as aged 70–74 years or clinically 
extremely vulnerable (group 4, 87.7% 
coverage); 2 210 110 aged 65–69 years 
(group 5, 89.4% coverage); and all other 
priority groups had at least 32.5% vaccination 
coverage. Among the youngest of the priority 
groups (50–54 and 55–59 years of age) 
some of those vaccinated to date are likely 
health and care workers. A total of 3 012 051 
patients, most likely health and care 
workers, were identified as being vaccinated 
but not assigned to one of the priority groups. 
Of all those vaccinated, 12 080 194 (57.9%) 
received the AstraZeneca-Oxford vaccine 
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as their first dose, 8 691 536 (41.7%) the 
Pfizer-BioNTech vaccine, with the remainder 
receiving a vaccine where the brand was not 
specified (n = 80 962). There were 1 257 914 
patients who received a second dose (6.0%) 
(data available from the GitHub repository).14 
Key demographic and clinical 
characteristics of priority group 2
The substantially larger priority group 2 
was offered vaccination alongside group 1. 
Priority group 2 included those aged 
≥80 years who were not known to be 
living in a care home, and rapidly reached 
90% coverage over the first 8 weeks of 
the vaccination campaign, with a further 
increase of 4.7% over the remaining weeks 
of the study period (data available from 
the GitHub repository).14 A breakdown 
of the proportion of patients vaccinated 
by 17 March in this group by various 
demographic and clinical categories is 
provided in Table 2 and Figures 2 and 3. 
Vaccination was less common among 
those living in the most deprived postcode 
areas (90.7% in the most deprived quintile 
compared to 96.6% in the least deprived, 
Figure 2a).
Across broad ethnic groups (Figure 2b), 
the proportion vaccinated to date was 
highest among White ethnicity (96.2%); 
lowest among Black ethnicity (68.3%); 
77.7%–84.6% among patients of mixed, 
other, and South Asian ethnicities; and 
94.1% among those with unknown ethnicity; 
ethnicity coding was 63.9% complete in this 
age group. Vaccination coverage in detailed 
ethnic groups ranges from 96.7% in the 
White — British group to 59.8% in the Black 
or Black British — African group (Table 2). 
Vaccination coverage was initially lower 
among those with obesity (Figure 3a); 
however, this gap had largely resolved by 
mid-March 2021. Vaccination coverage 
was slightly higher among patients with 
other physical comorbidities such as 
chronic respiratory disease (Figure 3b), 
cardiac disease, or chronic kidney disease. 
Vaccination coverage was substantially 
lower among those living with severe 
mental illness (89.5%, Figure 3c) and 
learning disabilities (91.4%, Figure 3d), with 
some improvements over time. 
Key demographic and clinical 
characteristics of other priority groups
Detailed tables and charts of breakdowns 
for all other priority groups are available on 
the GitHub repository.14 The differences by 
demographic and clinical features observed 
in priority group 2 were broadly reflected 
in other priority groups. Key exceptions 
were that the lower-priority groups, not yet 
widely vaccinated, had a different pattern 
of discrepancy by ethnicity, with the South 
Asian population most vaccinated. This 
pattern was also seen in several other 
groups during early stages of the campaign, 
before widespread targeting of individual 
groups, such as the 70–74 and 75–79 
age groups. Recent improvements in the 
vaccination coverage of the Bangladeshi 
community was also noted, where an 
acceleration with respect to other ethnic 
groups was seen from around 16 February, 
particularly noticeable in priority groups 4, 
6, 7, 8, and 9.
Table 1. Vaccination coverage among 95% of the population of registered patients in England, according to 
COVID-19 vaccination priority groups, at 17 March 2021a
 Vaccinated at  Vaccinated at  Vaccinated at  Increase in coverage in 
Priority group 17 March, % 17 March, n Population 10 March, % latest week, % point
1. In care home 91.2 275 205 301 889 90.4 0.7
2. Aged ≥80 years 94.7 2 422 476 2 558 906 94.5 0.2
3. Aged 75–79 years 94.7 1 865 927 1 970 234 94.5 0.2
4. CEV or aged 70–74 years 87.7 4 113 627 4 690 203 86.7 1.0
5. Aged 65–69 years 89.4 2 210 110 2 472 862 87.6 1.7
6. At-risk 68.7 2 861 474 4 165 987 60.1 8.6
7. Aged 60–64 years 76.9 1 644 636 2 139 200 63.7 13.2
8. Aged 55–59 years 51.6 1 438 913 2 790 228 30.2 21.4
9. Aged 50–54 years 32.5 1 008 273 3 097 668 22.1 10.5
Other 8.9 3 012 051 33 743 290 8.0 1.0
Population 36.0 20 852 692 57 930 467 32.6 3.4
aAll ages are included. CEV = clinically extremely vulnerable.
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Factors associated with time to COVID-19 
vaccination
For the multivariable model, 6 701 393 
people aged ≥70 years were included 
(Supplementary Figure S1). Associations 
between patient-level factors and having a 
COVID-19 vaccine are shown in Figure 4 
and Supplementary Table S1. Of note, after 
adjustment for modelled demographic 
and clinical characteristics, the chance of 
being vaccinated was significantly higher 
in those living in less deprived areas (least 
deprived IMD quintile versus most deprived 
hazard ratio [HR] 1.31, 95% CI = 1.31 to 1.32; 
P<0.0001), and smaller in those from ethnic 
minority groups (for example, compared 
with White — any other White background, 
HR 0.69, 95% CI = 0.69 to 0.70; Black or 
Black British — African, HR 0.40, 95% 
CI = 0.40 to 0.41). 
All of the clinical risk groups were 
associated with a higher chance of being 
vaccinated, with the exception of chronic 
neurological diseases (HR 0.93, 95% CI = 0.93 
to 0.93) and severe mental illness (HR 0.75, 
95% CI = 0.74 to 0.75) (Figure 4). 
DISCUSSION
Summary
The NHS in England has rapidly responded 
to the availability of COVID-19 vaccines 
and administered a substantial number of 
doses in the first 100 days of the vaccination 
campaign. In this study, 20 852 692 
patients (36.0% of patients registered in 
97% of GP practices in England) received 
at least one vaccine dose by 17 March 
2021, including 94.7% of eligible patients 
aged ≥80 years (priority group 2). However, 
ethnic minorities in priority group 2 were 
substantially less likely to be vaccinated, 
and those living in more socioeconomically 
deprived areas generally had lower vaccine 
coverage. Similarly, these patterns were 
broadly observed across the majority of 
priority groups. Furthermore, in those aged 
≥80 years, patients with pre-existing medical 
conditions were equally likely, or more likely, 
to have received a vaccine, across all groups 
of pre-existing medical problems, with two 
exceptions: vaccination was lower among 
patients living with severe mental illness 
and learning disabilities. Similarly, in a risk-
adjusted model, chance of vaccination was 
significantly lower among those living in 
deprived areas, those from ethnic minority 
groups, those with chronic neurological 
disease (including learning disability), and 
those with severe mental illness.
A total of 3 012 051 people who received 
a vaccination, most likely health and care 
workers, were not identified as part of any 
priority group. Usage was split between two 
vaccine brands, Pfizer-BioNTech (41.7%, 
n = 8 691 536) and AstraZeneca-Oxford 
(57.9%, n = 12 080 194). A second dose of the 
vaccine was received by 6.0% (n = 1 257 914). 
Strengths and limitations
The key strengths of this study are the scale, 
detail, completeness, and timeliness of the 
underlying raw EHR data. This analysis was 
executed across the full dataset of all raw, 
pseudonymised, single-event-level clinical 






























































































































































































































Figure 1. a) Cumulative daily total number of patients 
(millions) in England receiving at least one vaccination 
recorded in OpenSAFELY on 17 March 2021; across 
the whole population (All) and split according to 
whether patients were known to be part of a priority 
group or not (excluding occupational eligibility). b) 
Cumulative daily proportion (%) of patients receiving 
at least one COVID vaccine dose by Joint Committee 
on Vaccination and Immunisation priority groups 
(excluding occupational eligibility) in England recorded 
in OpenSAFELY on 17 March 2021. 
CEV = clinically extremely vulnerable.
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Table 2. COVID vaccinations among priority group 2 (aged 80 years and over population not resident in care 
homes) as at 17 March 2021, according to demographic and clinical featuresa 
 Vaccination, %  Vaccination, n  Vaccination, %  Increase in coverage in 
 at 17 March at 17 March Population, n 10 March latest week, %
Overall 94.7 2 422 476 2 558 906 94.5 0.2
Sex     
Female 94.5 1 400 532 1 481 970 94.3 0.2
Male 94.9 1 021 944 1 076 936 94.8 0.1
Ethnicity     
White — British 96.7 1 391 404 1 439 613 96.5 0.1
White — Irish 93.6 19 579 20 923 93.4 0.2
White — any other White background 86.5 47 551 54 992 86.3 0.2
Mixed — White and Black Caribbean 75.0 2779 3703 74.5 0.6
Mixed — White and Black African 68.3 798 1169 67.1 1.2
Mixed — White and Asian 86.2 1134 1316 85.6 0.5
Mixed — any other mixed background 81.5 1918 2352 81.2 0.3
Asian or Asian British — Indian 89.9 29 456 32 753 89.7 0.2
Asian or Asian British — Pakistani 76.9 12 859 16 723 76.0 0.9
Asian or Asian British — Bangladeshi 81.3 3969 4879 80.5 0.9
Asian or Asian British — any other Asian background 82.3 9548 11 599 82.0 0.4
Black or Black British — Caribbean 71.3 16 681 23 387 70.6 0.7
Black or Black British — African 59.8 5152 8617 59.0 0.8
Black or Black British — any other Black background 69.8 1750 2506 69.0 0.8
Other ethnic groups — Chinese 78.1 3199 4095 77.9 0.2
Other ethnic groups — any other ethnic group 78.3 5348 6832 77.8 0.5
Patients with any other ethnicity code 95.4 377 566 395 654 95.3 0.2
Ethnicity not stated 92.9 15 344 16 513 92.7 0.2
Ethnicity not recorded 93.2 476 336 511 182 93.0 0.2
Ethnicity (broad categories)     
White 96.2 1 458 548 1 515 535 96.1 0.1
Mixed 77.7 6650 8554 77.3 0.5
South Asian 84.6 55 846 65 975 84.2 0.5
Black 68.3 23 590 34 517 67.6 0.8
Other 78.3 8561 10 934 77.9 0.4
Unknown 94.1 869 260 923 363 94.0 0.2
Index of Multiple Deprivation     
1 (most deprived) 90.7 309 190 340 928 90.4 0.3
2 92.9 402 836 433 622 92.7 0.2
3 95.0 514 682 541 737 94.8 0.2
4 95.9 564 410 588 546 95.8 0.1
5 (least deprived) 96.6 612 731 634 340 96.5 0.1
Unknown 94.5 18 613 19 691 94.3 0.2
Clinical risk groups     
Patients in any clinical risk group 95.7 1 766 590 1 846 677 95.5 0.2
Patients with immunosuppression 96.6 107 184 110 999 96.4 0.2
Patients with CKD 95.9 750 820 782 705 95.8 0.2
Patients who have chronic respiratory disease 96.0 294 413 306 810 95.8 0.2
Patients with diabetes 94.8 492 982 519 862 94.6 0.2
Patients with chronic liver disease 95.4 44 618 46 746 95.2 0.2
Patients with chronic neurological disease (including 95.4 408 730 428 400 95.2 0.2 
  stroke/TIA)
Patients with chronic heart disease 96.1 1 042 034 1 084 643 95.9 0.2
Patients with asplenia or dysfunction of the spleen 96.8 19 950 20 615 96.7 0.1
Patients with learning disability 91.4 1190 1302 91.4 0.0
Patients with severe mental health 89.5 15 582 17 409 89.1 0.4
Other groups      
Patients who are clinically extremely vulnerable 93.6 706 629 754 789 93.4 0.2
Patients with morbid obesity 93.8 32 837 35 014 93.5 0.3
aValues <7 suppressed. Patient counts are rounded to the nearest 7. CKD = chronic kidney disease. TIA = transient ischaemic attack.
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at all NHS GP practices in England using 
EMIS and TPP software; this includes data 
on all tests, treatments, diagnostic events, 
and other salient clinical and demographic 
information. This was achieved by developing 
and deploying data management and data 
analysis software inside the EHR vendors’ 
infrastructure, where the patient data 
already resides. As a consequence of this, 
OpenSAFELY can deliver insights into health 
service activity and clinical outcomes in near 
real time: raw data can be processed into a 
completed analysis within days of a clinical 
event being entered into the patient’s record. 
Another key strength is that all eligible 
patients were identified in each JCVI priority 
group by directly implementing the full 
official SNOMED-CT codelists and logic for 
the national PRIMIS COVID-19 vaccination 
uptake reporting specification, thus ensuring 
that the cohorts are perfectly in line with 
national procedures and GP expectations. 
Some limitations to this analysis are 
recognised. The population, although 
extremely large, may not be fully 
representative of the full eligible population: 
it does not include individuals not registered 
with a general practice; or the 4% of patients 
registered at practices not using TPP and 
EMIS. Primary care records, while detailed 
and longitudinal, can be incomplete on 
certain patient characteristics. 
Occupation is generally not available in 
the EHR so it was not possible to assess 
the eligibility in priority groups 1 or 2 where 
this is based on occupation. This means 
that it was not possible to determine the 
appropriateness of vaccination for those in 
the ‘other’ group. For patients aged ≥80 years, 
36.2% and 0.8% had missing ethnicity or 
IMD information, respectively. In the weekly 
COVID-19 vaccination coverage report a 
different ethnicity codelist and additional 
sources of data within OpenSAFELY-TPP 
are used to reduce missing data to <10% for 
ethnicity.11 This method will be implemented 
within OpenSAFELY-EMIS when possible. 
As a federated analysis has been carried 
out across two EHR vendor’s systems, it is 
possible that a very small number of patient 
records are duplicated; however, this has 
now been established to represent <0.03% 
of the total patient count. The ascertainment 
of vaccination status relies on the vaccination 
administration electronic message being 
successfully received into the primary care 
record; while these numbers are consistent 
with national figures, methods are being 
explored to also cross-validate this against 
other sources of person-level vaccination 
data, broken down by vaccination site type. 
Finally, there is currently no well-
validated person-level data to identify 
individuals resident in a care home: this is 
a limitation for all UK healthcare database 
studies. The method used for identifying 
care home residents in this analysis — a 
clinical code as detailed by the national 
reporting specification — will lead to under-
ascertainment.15 The authors of the current 
study are launching a programme of work, in 
collaboration with the UK health data science 
community, to describe and validate the best 
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Figure 2. Cumulative trends in demographic features 
of the 80 years and older population receiving their 
first COVID vaccination. a) COVID vaccinations among 
the age 80 years and over population by Index of 
Multiple Deprivation. b) COVID vaccinations among the 
age 80 years and over population by ethnicity (broad 
categories).
IMD = Index of Multiple Deprivation.
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residents, to produce a better understanding 
of their health outcomes. 
Comparison with existing literature
The UK had already administered 
40.49 vaccines per 100 people by 17 March 
2021, one of the fastest vaccination 
programmes in the world.16 NHS England 
publish report counts of vaccines delivered 
using vaccination data extracted from the 
NIMS and report that 21 886 125 first dose 
vaccinations had been administered by 
17 March 2021:17 this is in line with the 
finding in this current study of 20 852 692 
patients vaccinated using OpenSAFELY 
data. It is reasonable to expect marginal 
differences in the count of patients 
vaccinated, and the proportions vaccinated, 
between different summary reports from 
different analytic teams, because of minor 
differences in the speeds of data flow, and 
in the ascertainment of denominators. 
The total OpenSAFELY population figure is 
57.9 million, which is approximately 95% of 
the NHS Digital estimate for the number of 
people registered in England with an NHS 
GP in March 2021 (60.65 million).18 It is noted 
that this figure is higher than the latest 
Office for National Statistics (ONS) estimated 
population of England (56.2 million):19 
the difference between ONS population 
estimates and NHS-registered populations 
is a well-recognised issue and may be 
caused by over-counting at GP practices, 
differences in definition, and under-counting 
by the ONS, or a combination of all three.20,21 
To the authors’ knowledge, this manuscript, 
an update of the 27 January 2021 preprint 
covering only OpenSAFELY-TPP patients 
(40% of the population),22 is the first study 
to describe in detail the demographic and 
clinical features of those who have been 
Figure 3. Cumulative trends in clinical characteristics 
of priority group 2 (age 80 years and over population 
and not resident in a care home) receiving their first 
COVID vaccination. a) COVID vaccinations among the 
age 80 years and over population by ‘morbid obesity’. 
b) COVID vaccinations among the age 80 years and 
over population by ‘chronic respiratory disease’. 
c) COVID vaccinations among the age 80 years and 
over population by ‘severe mental illness’. d) COVID 
vaccinations among the age 80 years and over 
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vaccinated by the NHS England COVID- 19 
vaccination campaign; and the only study 
to report on variation in vaccination by 
fine-grained clinical characteristics, 
because OpenSAFELY can provide detailed 
information about the demographics and 
clinical conditions of those vaccinated from 
each patient’s full pseudonymised EHR, 
which is not available within NIMS. 
The finding of lower vaccination coverage 
in Black and Asian groups is concerning: it 
is also consistent with previous research on 
variation in vaccine coverage between ethnic 
groups during other vaccination campaigns 
historically,23–25 and with survey data on 
intention to accept the COVID-19 vaccine.26–29 
The association reported here with deprivation 
(aged ≥80 years: most deprived 90.7%, least 
deprived 96.6% [5.9% difference]) resembles 
other national vaccination campaigns (for 
example, pneumococcal polysaccharide 
vaccine) of coverage in those aged ≥65 years: 
most deprived 68.4%, least deprived 70.9% 
[2.5% difference]; shingles coverage at 
age 70 years: 41.0% versus 46.4% [5.4% 
difference]),30 and may somewhat even out 
during the course of the rapid vaccine rollout. 
Implications for research and practice 
The reasons underpinning variation in 
COVID-19 vaccination coverage are not yet 
understood, and information presented here 
should not be misinterpreted as a criticism 
of the rapidly established NHS vaccination 
campaign. Further research is needed to 
understand and address the observed lower 
vaccination coverage among patients from 
more deprived areas, and the striking disparity 
between ethnic groups. The initial preprint 
on 27 January 2021 and this author group’s 
regular updates11,22 have received substantial 
media coverage, particularly with regards 
to the differences in vaccinations between 
different ethnic communities.31–34 The NHS, 
government, and communities themselves 
have introduced targeted activities to address 
the gap including vaccination at places of 
worship,35 webinars led by community 
leaders to tackle misinformation,36 and 
targeted funding for groups with remit for 
Figure 4. Estimated hazard ratios (HR) for each 
potential risk factor from a multivariable Cox model, 
stratified by GP practice. All HRs are adjusted for all 
other factors listed. 
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tackling any health inequalities.37,38 The 
authors note the accelerated increase in 
the Bangladeshi community from mid-
February, which may represent targeted 
action by a community group and/or a local 
NHS organisation. The regular OpenSAFELY 
vaccination coverage reports can support 
assessment of the success of these activities 
in increasing vaccination coverage.
It is reassuring to see that those with a 
previous history of various medical problems 
are being vaccinated at the same rate as 
other patients: in particular it is reassuring to 
see no evidence that the vaccine programme 
is currently missing those with serious 
physical health problems who are at highest 
risk of death from COVID-19. The lower 
vaccination coverage among patients living 
with severe mental illness and learning 
disabilities is concerning: this may reflect 
challenges around access, including for 
those currently living in institutional settings. 
However, in the latest weeks there was 
evidence of the vaccination gap narrowing 
in these groups (Figures 3c and 3d). In late 
February the JCVI recommended expanded 
vaccine access for all people on the GP 
learning disability register as well as adults 
with other related conditions, including 
cerebral palsy. This update of the previous 
advice was based on OpenSAFELY analysis 
showing a higher risk of mortality in those 
with learning disabilities39 and the JCVI 
anticipated that an additional 150 000 people 
would receive the vaccine sooner as a result 
of this advice.40 
The authors note that all findings in the 
present study are from the first 100 days of 
a major national vaccination programme. 
Very substantial changes in coverage among 
different groups are to be expected over the 
coming months. Weekly vaccine coverage 
reports are being shared by this author group 
to assist in monitoring and targeting vaccine 
initiatives along with machine-readable 
outputs for re-use in different formats (www.
opensafely.org/covid-vaccine-coverage).
More broadly, the UK has an unusually 
large volume of very detailed longitudinal 
patient data, especially through primary 
care. The authors believe the UK has a 
responsibility to the global community to 
ensure that these data are used to inform 
response to the COVID-19 pandemic, in a 
timely manner, while maintaining the security 
of individual health records and ensuring the 
full transparency of all actions on the data to 
build public trust. To this end, codelists and 
code for data management and data analysis 
can only be executed on OpenSAFELY after 
first being made available at GitHub.com/
openSAFELY before execution; this is then 
shared publicly under open licences for 
review and re-use either at, or before, the 
time when results are reported.
In conclusion, the NHS in England 
has rapidly deployed a mass vaccination 
campaign. Targeted activity may be needed 
to address lower vaccination coverage 
observed among certain key groups: ethnic 
minorities, those living in areas of higher 
deprivation, and individuals living with severe 
mental illness or learning disabilities. Live 
data monitoring is likely to help support 
those on the frontline making complex 
operational decisions around vaccine rollout.
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